David A. Siegel Ultragenyx Pharmaceutical Inc. Transaction History

Two Sigma Advisers, LP

$47 Billion
Q3 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 517,700 shares of RARE stock, worth $17.1 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

517,700

Previous 860,400 39.83%

Holding current value

$17.1 Million

Previous $31.3 Million 50.22%

% of portfolio

0.03%

Previous 0.07%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$26.31 - $41.44 $9.02 Million - $14.2 Million	-342,700 Reduced 39.83%	517,700 $15.6 Million
Q2 2025 Aug 14, 2025	SELL	$31.06 - $39.3 $2.39 Million - $3.02 Million	-76,800 Reduced 8.19%	860,400 $31.3 Million
Q1 2025 May 15, 2025	BUY	$36.21 - $45.78 $858,177 - $1.08 Million	23,700 Added 2.59%	937,200 $33.9 Million
Q4 2024 Feb 14, 2025	SELL	$42.07 - $57.72 $3.13 Million - $4.29 Million	-74,300 Reduced 7.52%	913,500 $38.4 Million
Q3 2024 Nov 14, 2024	BUY	$40.21 - $59.36 $21.9 Million - $32.4 Million	545,600 Added 123.38%	987,800 $54.9 Million

Q2 2024 Aug 14, 2024	SELL	$37.42 - $51.61 $224,520 - $309,660	-6,000 Reduced 1.34%	442,200 $18.2 Million
Q1 2024 May 15, 2024	BUY	$43.02 - $53.69 $11.2 Million - $13.9 Million	259,300 Added 137.27%	448,200 $20.9 Million
Q4 2023 Feb 14, 2024	SELL	$31.73 - $49.19 $1.29 Million - $2 Million	-40,600 Reduced 17.69%	188,900 $9.03 Million
Q3 2023 Nov 14, 2023	SELL	$34.92 - $46.66 $9.11 Million - $12.2 Million	-261,000 Reduced 53.21%	229,500 $8.18 Million
Q2 2023 Aug 14, 2023	SELL	$37.35 - $52.15 $276,390 - $385,910	-7,400 Reduced 1.49%	490,500 $22.6 Million
Q1 2023 May 15, 2023	BUY	$36.99 - $48.71 $1.38 Million - $1.81 Million	37,200 Added 8.07%	497,900 $20 Million
Q4 2022 Feb 14, 2023	BUY	$33.72 - $46.33 $13.8 Million - $19 Million	409,300 Added 796.3%	460,700 $21.3 Million
Q3 2022 Nov 14, 2022	BUY	$39.96 - $66.14 $2.05 Million - $3.4 Million	51,400 New	51,400 $2.13 Million
Q4 2021 Feb 14, 2022	SELL	$73.71 - $87.86 $5.12 Million - $6.1 Million	-69,400 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$77.92 - $102.4 $5.34 Million - $7.01 Million	-68,500 Reduced 49.67%	69,400 $6.26 Million
Q2 2021 Aug 16, 2021	BUY	$92.19 - $115.71 $534,702 - $671,118	5,800 Added 4.39%	137,900 $13.1 Million
Q1 2021 May 17, 2021	BUY	$106.9 - $167.73 $7.74 Million - $12.1 Million	72,400 Added 121.27%	132,100 $15 Million
Q4 2020 Feb 16, 2021	BUY	$84.4 - $177.39 $1.88 Million - $3.96 Million	22,300 Added 59.63%	59,700 $8.26 Million
Q3 2020 Nov 16, 2020	SELL	$72.98 - $90.0 $138,662 - $171,000	-1,900 Reduced 4.83%	37,400 $3.07 Million
Q2 2020 Aug 14, 2020	BUY	$46.91 - $78.22 $1.84 Million - $3.07 Million	39,300 New	39,300 $3.07 Million

Others Institutions Holding RARE

# of Institutions

348

Shares Held

88.2M

Call Options Held

2.19M

Put Options Held

1.04M

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $2.32B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account